Results 131 to 140 of about 57,330 (350)
Binder's Syndrome also known as Maxillo-Nasal Dysplasia is a developmental disorder primarily affecting the anterior part of the maxilla and nasal complex (nose and jaw). It is a rare disorder and the causes are unclear.
Babu, SG +3 more
core
Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19? [PDF]
Takashi SAKAIDA +4 more
openalex +1 more source
ABSTRACT Primary cutaneous B‐cell lymphomas (CBCL) represent a clinically and biologically heterogeneous group of extranodal non‐Hodgkin lymphomas confined to the skin at the time of diagnosis. They account for approximately 25% of all primary cutaneous lymphomas and are subclassified into distinct entities according to the World Health Organization ...
A. Bernardelli +5 more
wiley +1 more source
Drug-induced anti-Ro positive subacute cutaneous lupus in a man treated with olmesartan [PDF]
A 66-year-old man presented to the outpatient dermatology clinic with a chief complaint of a pruritic rash on his upper trunk and proximal upper extremities, which had been present for three weeks.
Farsi, Maheera +4 more
core
Fixed Drug Eruption due to Fluconazole: Not so uncommon Now-a-days
Ranjita Santra +2 more
openalex +1 more source
A randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures. Abstract Objectives This randomized, double‐blind, placebo‐controlled study (NCT04557085), conducted in China, Japan, and the Republic of Korea, evaluated the efficacy and safety of ...
Sang Kun Lee +20 more
wiley +1 more source
Atezolizumab-induced psoriasiform drug eruption successfully treated with ixekizumab: a case report and literature review [PDF]
L Gleason +4 more
openalex +1 more source
Graphical representation of article highlights, including early response rates with adjunctive cenobamate. Abstract Objective To examine early responses to cenobamate therapy using prospective data from a dose–response study in Asian patients with focal seizures (YKP3089C035, C035) that employed a titration regimen starting at 12.5 mg/day.
Kensuke Kawai +19 more
wiley +1 more source

